Concurrent Investment Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
– Sell
-9,378
Closed -$270K – 995
2024
Q1
$270K Sell
9,378
-1,656
-15% -$49.8K 0.01% 702
2023
Q4
$362K Buy
+11,034
New +$300K 0.02% 588

Other funds holding ARKG

Concurrent Investment Advisors's ARKG Position: Q2 2024 in Review

Concurrent Investment Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2024, closing a stake of 9,378 shares — an estimated $270K sold.

Concurrent Investment Advisors first reported a position in ARKG in Q4 2023 and held it in 2 quarters. The position peaked at $362K in Q4 2023. 263 funds tracked by Wall St. Rank hold ARKG as of Q2 2024.

  • Concurrent Investment Advisors reported no remaining ARK Genomic Revolution ETF position as of Q2 2024 after selling out during the quarter.
  • Concurrent Investment Advisors sold 9,378 ARK Genomic Revolution ETF shares in Q2 2024, an estimated $270K.
  • Concurrent Investment Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2023 and held it in 2 quarters.
  • Concurrent Investment Advisors's ARK Genomic Revolution ETF position peaked at $362K in Q4 2023.
  • 263 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2024.

Based on Concurrent Investment Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.